权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Studies on chemotherapy of advanced or recurrent head and neck cancer for purposes of prolongation of life with improvement of quality of life

以延长生命和改善生活质量为目的的晚期或复发性头颈癌化疗的研究

基本信息

批准号：
62570784
负责人：
INUYAMA Yukio
金额：
$ 1.41万
依托单位：
Department of Otorhinolaryngology, School of Medicine, Keio University
依托单位国家：
日本
项目类别：
Grant-in-Aid for General Scientific Research (C)
财政年份：
1987
资助国家：
日本
起止时间：
1987 至 1988
项目状态：
已结题

项目摘要

1. Fundamental research; We tried to evaluate the effect of combination of carboplatin (CBDCA) and peplomycin (PEP) on experimental study defore applying the combination therapy clinically. Male BALB/c nude mice and three unde mouce-grown squamous cell carcinoma of head and neck origin were used in the present study. The results revealed statistically no different anti-tumor activity between the combination therapies on three nude mouse-grown human squamous cell carcinomas. If so, this combination may be more useful clinically in terms of lower nephrotoxicity resulting in no phdration durig the treatment.2. Clinical research: In our department, 109 patients with advanced or recurrent head and neck cancer received palliative chemotherapy for the purpose of prolonging life and improving quality of life throughout the past 11 years. Single or combined agents including CDDP, bleomycin analogs, methotrexate, vincristine etc were used. The 5-year survival ratge was 3.3% in this series. We also evaluated the quality of life of all patients receiviving chemotherapy. An improvement of quality of life was observed in 39 of them. The lives of the 30 patients, whose performance status improved after chemotherapy, were prolonged and they enjoyed their home lives while receiving treatment at the outpatient level. The use of chemotherapy at the outpatient level will be increasingly important in the future. From our longtime experiences on chemotherapy of the head and neck cancer, we recognized several combinations in which noncross-resistance was observed. They include UFT+BM therapy (bleomycin, mitomycin C), UFT-M therapy (UFT, mitomycin C) + CP therapy (CDDP, PEP), VMB therapy (vincristine, methotrexate, bleomycin) + CP therapy etc. At present, we recommend noncross-resistant sequential chemotherapy consisting ofm VMP therapy (vincristine, methotrexate,PEP) or VDMP therapy (vindesine, methotrexate, PEP) nad CDDP containing regimen like CP therapy or CDDP + 5-fluorouracil.

1、基础研究；在临床应用联合治疗之前，我们试图通过实验研究评估卡铂（CBDCA）和培普霉素（PEP）联合治疗的效果。本研究使用雄性 BALB/c 裸鼠和三只小鼠生长的头颈部鳞状细胞癌。结果显示，联合疗法对三种裸鼠生长的人类鳞状细胞癌的抗肿瘤活性在统计学上没有差异。如果是这样，这种组合在临床上可能更有用，因为它可以降低肾毒性，从而在治疗过程中无需进行水合作用。2．临床研究：11年来，我科对109例晚期或复发头颈癌患者进行了姑息化疗，以延长生命、提高生活质量。使用单药或联合药物，包括CDDP、博来霉素类似物、甲氨蝶呤、长春新碱等。该系列的 5 年生存率为 3.3%。我们还评估了所有接受化疗的患者的生活质量。其中 39 人的生活质量得到改善。化疗后体能状况改善的30名患者的生命得到了延长，他们在门诊接受治疗的同时也享受了家庭生活。未来，门诊化疗的使用将变得越来越重要。根据我们对头颈癌化疗的长期经验，我们发现了几种观察到非交叉耐药性的组合。包括UFT+BM疗法（博莱霉素、丝裂霉素C）、UFT-M疗法（UFT、丝裂霉素C）+CP疗法（CDDP、PEP）、VMB疗法（长春新碱、甲氨蝶呤、博来霉素）+CP疗法等。甲氨蝶呤，PEP）或 VDMP 治疗（长春地辛，甲氨蝶呤，PEP）和包含 CDDP 的方案，如 CP 治疗或 CDDP + 5-氟尿嘧啶。